U.S. launches global pandemic-drug strategy with private-sector partnerships
H.R. 7879 — SUPER BUGS Act of 2026 · Filed by Mike Levin (D-CA) · 3 cosponsors · Introduced Mar 9, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill directs the Secretary of State, working with the Department of Health and Human Services and other agencies, to develop a strategy within 18 months for securing international cooperation—from foreign governments, multilateral organizations, and private entities—to develop and commercialize drugs and medical products to fight pandemic diseases and antimicrobial-resistant bacteria. The strategy must coordinate funding, research, and regulatory pathways across countries and organizations, prioritize products with the greatest public health impact, and include arrangements with U.S. companies and public-private partnerships.
Why we flagged it
The bill's core function is to mandate a federal strategy for international cooperation on pandemic and antimicrobial-resistance product development. It is a planning and coordination instrument, not a direct appropriation, subsidy, or regulatory change. The mechanism is transparent: formulate a strategy, report to Congress, enter into arrangements with foreign and private partners.
What the text implies
- The bill does not appropriate funds or mandate spending; it only requires a strategy and arrangements. Implementation and funding depend on future appropriations and voluntary participation by foreign governments and private entities, creating execution risk.
- The phrase 'alternative payment models' and 'coverage and reimbursement pathways' may enable advance market commitments or other mechanisms that guarantee revenue to private firms regardless of product uptake, potentially shifting financial risk from companies to taxpayers.
- The strategy must 'harmonize' with existing efforts (National Strategy for Combating Antibiotic-Resistant Bacteria, National Biodefense Strategy), but the bill does not specify how conflicts between those strategies and this one will be resolved, leaving room for bureaucratic discretion.
- The bill emphasizes 'equitable contributions based on budgets and technical expertise' but does not define 'equitable' or establish enforcement mechanisms, potentially allowing wealthier nations or organizations to dominate decision-making despite the stated principle.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
The bill creates a coordinated international framework to accelerate development of pandemic and antibiotic-resistance treatments, which directly protects public health and reduces outbreak risk to U.S. citizens. It emphasizes equitable access, sustainable capacity-building in partner countries, and efficient allocation of scarce research funds—all public goods. No liability shields, immunity grants, or private carve-outs are present; the bill is a planning and coordination mandate with no restr
Who stands to gain
- pharmaceutical companies
- biotechnology firms
- medical device manufacturers
- contract research organizations
Named in the bill
Secretary of State, Secretary of Health and Human Services, Centers for Disease Control and Prevention, Foreign Affairs Committee (House), Health, Education, Labor, and Pensions Committee (Senate), Foreign Relations Committee (Senate), Energy and Commerce Committee (House), U.S. companies (private sector), foreign governments, multilateral organizations
Where it stands
3 cosponsors: 2 Republicans, 1 Democrats.
- Mar 9, 2026 — Introduced · Congress.gov: “Introduced in House”
- Mar 9, 2026 — Referred to House Committee on Foreign Affairs · Congress.gov: “Referred to the House Committee on Foreign Affairs”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
2 lobbying clients named this bill on 2 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $320,000 in lobbying spend. A filing names 14 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 41% of bills with at least one filing.
Mike Levin, the sponsor, reported $429,156 in PAC receipts in the 2026 cycle.
- Cystic Fibrosis Foundation — $270,000 on 1 filing
- American Society for Microbiology — $50,000 on 1 filing
Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (5,891 characters) on Aug 19, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Jun 2026 to Jun 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jul 20, 2026 · page rendered 2026-10-20.
“U.S. launches global pandemic-drug strategy with private-sector partnerships” QuorumCivic. https://share.quorumcivic.app/bill/119/hr7879 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.